Cryoablation Versus BCG Instillation Therapy for High-risk NMIBC
- Disease/Condition
- Bladder Cancer
- Drug/Device/Intervention
- Transurethral cryoablation
- Study type
- Interventional
- Intervention type
- procedure
- Primary sponsor
- Huashan Hospital
- Phase
- N/A
- Start date
- Mar 18, 2024
- End date
- Mar 18, 2026
- Enrollment
- 190 participants
Tumor residual rate
This trial plans to enroll 190 eligible patients and randomize them into two groups with a
 1:1 ratio, with 95 patients in each group. The experimental group will receive immediate
 cryoablation therapy at the resection site after TUR, while the control group will only
 undergo TUR and receive conventional BCG instillation therapy postoperatively. Both groups of
 subjects will undergo Re-TURBT or cystoscopy 10-12 weeks after surgery to compare the
 tumor-free residual rates and adverse events between the two groups.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06324058
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06324058 through Pure Global AI's free database. This phase not specified trial is sponsored by Huashan Hospital and is currently Not yet recruiting. The study focuses on Bladder Cancer. Target enrollment is 190 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.